TY  - JOUR
AU  - Nikolić-Vukosavljević, Dragica
AU  - Todorović-Raković, N
AU  - Demajo, Miroslav
AU  - Ivanović, Vesna
AU  - Neskovic, B
AU  - Markicevic, M
AU  - Nešković-Konstantinović, Zora
PY  - 2004
UR  - https://vinar.vin.bg.ac.rs/handle/123456789/2869
AB  - A pilot study was conducted to assess whether plasma levels of transforming growth factor-beta 1 (TGF-beta 1) might facilitate biological subgrouping of postmenopausal metastatic breast cancer patients, and, accordingly, its applicability in clinical oncology. This study included 29 postmenopausal metastatic breast cancer patients. Plasma TGF-beta 1 levels were detected by enzyme-linked immunosorbent assay (ELISA). Estrogen and progesterone receptors were assayed by radioligand binding, in accordance with the recommendation of the EORTC. Concentrations of 17-beta estradiol were determined by using ELISA-microwell method (DIALAB). Overall survival was followed for 24 months for each individual patient. Stratification of the patients by ER/PR status showed that 14 patients with estrogen receptor-negative, progesterone receptor-negative carcinomas displayed a statistically significant increase in plasma TGF-beta 1 levels when compared to plasma TGF-beta 1 levels of 6 patients with ER-positive, PR-positive carcinomas (P=0.04). In this study, 7 out of 14 patients with negative receptors status had no plasma TGF-beta 1 values overlapping with patients having positive receptors status. The TGF-beta 1 cut-off value was defined as the highest plasma TGF-beta 1 level of ER-positive, PR-positive patients: 3.28 ng/ml. This plasma TGF-beta 1 cut-off value defined low-risk subgroup of 19 patients (! 3.28 ng/ml) and high-risk subgroup of 10 patients ( GT 3.28 ng/ml) (P=0.047). Plasma TGF-beta 1-related survival was independent of the classical prognostic factors of metastatic breast cancer. Accordingly, a clinical significance of elevated plasma TGF-beta 1 levels may be suggested.
T2  - Clinical and Experimental Metastasis
T1  - Plasma TGF-beta 1-related survival of postmenopausal metastatic breast cancer patients
VL  - 21
IS  - 7
SP  - 581
EP  - 585
UR  - https://hdl.handle.net/21.15107/rcub_vinar_2869
ER  - 

@article{
author = "Nikolić-Vukosavljević, Dragica and Todorović-Raković, N and Demajo, Miroslav and Ivanović, Vesna and Neskovic, B and Markicevic, M and Nešković-Konstantinović, Zora",
year = "2004",
abstract = "A pilot study was conducted to assess whether plasma levels of transforming growth factor-beta 1 (TGF-beta 1) might facilitate biological subgrouping of postmenopausal metastatic breast cancer patients, and, accordingly, its applicability in clinical oncology. This study included 29 postmenopausal metastatic breast cancer patients. Plasma TGF-beta 1 levels were detected by enzyme-linked immunosorbent assay (ELISA). Estrogen and progesterone receptors were assayed by radioligand binding, in accordance with the recommendation of the EORTC. Concentrations of 17-beta estradiol were determined by using ELISA-microwell method (DIALAB). Overall survival was followed for 24 months for each individual patient. Stratification of the patients by ER/PR status showed that 14 patients with estrogen receptor-negative, progesterone receptor-negative carcinomas displayed a statistically significant increase in plasma TGF-beta 1 levels when compared to plasma TGF-beta 1 levels of 6 patients with ER-positive, PR-positive carcinomas (P=0.04). In this study, 7 out of 14 patients with negative receptors status had no plasma TGF-beta 1 values overlapping with patients having positive receptors status. The TGF-beta 1 cut-off value was defined as the highest plasma TGF-beta 1 level of ER-positive, PR-positive patients: 3.28 ng/ml. This plasma TGF-beta 1 cut-off value defined low-risk subgroup of 19 patients (! 3.28 ng/ml) and high-risk subgroup of 10 patients ( GT 3.28 ng/ml) (P=0.047). Plasma TGF-beta 1-related survival was independent of the classical prognostic factors of metastatic breast cancer. Accordingly, a clinical significance of elevated plasma TGF-beta 1 levels may be suggested.",
journal = "Clinical and Experimental Metastasis",
title = "Plasma TGF-beta 1-related survival of postmenopausal metastatic breast cancer patients",
volume = "21",
number = "7",
pages = "581-585",
url = "https://hdl.handle.net/21.15107/rcub_vinar_2869"
}

Nikolić-Vukosavljević, D., Todorović-Raković, N., Demajo, M., Ivanović, V., Neskovic, B., Markicevic, M.,& Nešković-Konstantinović, Z.. (2004). Plasma TGF-beta 1-related survival of postmenopausal metastatic breast cancer patients. in Clinical and Experimental Metastasis, 21(7), 581-585.
https://hdl.handle.net/21.15107/rcub_vinar_2869

Nikolić-Vukosavljević D, Todorović-Raković N, Demajo M, Ivanović V, Neskovic B, Markicevic M, Nešković-Konstantinović Z. Plasma TGF-beta 1-related survival of postmenopausal metastatic breast cancer patients. in Clinical and Experimental Metastasis. 2004;21(7):581-585.
https://hdl.handle.net/21.15107/rcub_vinar_2869 .

Nikolić-Vukosavljević, Dragica, Todorović-Raković, N, Demajo, Miroslav, Ivanović, Vesna, Neskovic, B, Markicevic, M, Nešković-Konstantinović, Zora, "Plasma TGF-beta 1-related survival of postmenopausal metastatic breast cancer patients" in Clinical and Experimental Metastasis, 21, no. 7 (2004):581-585,
https://hdl.handle.net/21.15107/rcub_vinar_2869 .